News & Updates

Show Multimedia Only
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

03 Mar 2023 byStephen Padilla

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

03 Mar 2023
Infertility implicated in obesity-related reproductive cancers

Infertility implicated in obesity-related reproductive cancers

03 Mar 2023

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.

03 Mar 2023
How common is viral burden rebound in hospitalized COVID-19 patients with or without oral antiviral treatment?

How common is viral burden rebound in hospitalized COVID-19 patients with or without oral antiviral treatment?

03 Mar 2023 bySarah Cheung

A real-world study during Hong Kong’s Omicron BA.2.2 wave has shown that viral burden rebound is uncommon in hospitalized COVID-19 patients not requiring supplemental oxygen on admission, regardless of whether they were treated with nirmatrelvir/ritonavir or molnupiravir. However, immunocompromised patients, regardless of oral antiviral use, are more likely to have viral burden rebound.

03 Mar 2023